Related Content
- Tradjenta now available in U.S. pharmacies
- Walgreens' Pegus to discuss impact of diabetes management on healthcare costs
- Decision Resources: Bydureon could promote weight loss among patients
- Novo Nordisk's Victoza helps patients achieve blood-sugar control when switching from exenatide or sitagliptin
- Combining Lilly and Amylin drug with insulin intake found to promote weight loss
SAN DIEGO — Amylin Pharmaceuticals and Alkermes announced that their Type 2 diabetes treatment now is available by prescription in U.S. pharmacies.
Bydureon (exenatide extended-release for injectable suspension) received approval from the Food and Drug Administration on Jan. 27 as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes.
In line with the official launch, the drug makers said eligible patients will have access to the Bydureon Steady Savings Card to help offset co-pay costs by saving up to $50 per month for up to 24 months. Details about the program can be found here.
